Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal (BioPharma Dive.)
Memo Therapeutics
Private
Memo Therapeutics is a Swiss clinical-stage biotech developing antibody-based therapies for viral infections and cancer. Its lead asset is anti-BK virus (BKV) antibody for kidney transplant recipients, with additional programs in CMV and oncology.
Company Info
Sector:Biotechnology / Antibody Therapeutics
Headquarters:Schlieren, Switzerland
Founded:2017
Website:www.memotx.com/